mRNA Therapeutics

Abstract Lipid nanoparticles (LNPs) administered parenterally often show poor localization to multiple tissue types, including the pancreas and gastrointestinal (GI)...

Abstract Polymers offer a promising alternative to established lipid nanoparticles for therapeutic RNA delivery. Here, we introduce alkyl-chain-quaternized poly(vinylpyrrolidone-co-4-vinylpyridine) copolymers...

Biopharmaceutical excipients are the inactive substances added to biologic drug products to protect large, structurally fragile biomolecules, such as monoclonal...

Messenger RNA (mRNA) is intrinsically unstable due to spontaneous 2'-hydroxyl-mediated phosphodiester hydrolysis, with degradation rates accelerating at pH below 5.0...

This year, the 15th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology took place in Prague, Czech Republic. We show...

Abstract Ionizable aminolipids enable lipid nanoparticles (LNPs) to encapsulate nucleic acids at neutral pH and to release their cargo upon...

Abstract Since the first market authorization of RNA therapies, just eight years ago, the field has witnessed an extraordinary expansion,...

Abstract KRAS G12S mutations in non-small cell lung cancer (NSCLC) remain refractory to current targeted therapies, with few clinical options and...

Highlights PLGA/PBAE coordinates endosomal escape and timely mRNA release in APCs PLGA/PBAE enhances mRNA transfection in APCs and promotes immune...

Abstract Background: An efficient formulation of lipid nanoparticles (LNPs) is often considered crucial in the successful development of nucleic acid...